{
    "id": "5c5f2cef1a4c55d80b000022",
    "question": "There is no drug available to prevent HIV infection, Pre-exposure prophylaxis (PrEP), yes or no?",
    "options": {
        "A": "yes",
        "B": "no"
    },
    "answer": "B",
    "predict": "{\"step_by_step_thinking\": \"To answer this question, we need to evaluate the available information about HIV prevention and treatment options. Pre-exposure prophylaxis (PrEP) is a form of HIV prevention that involves taking antiretroviral medication daily to prevent HIV infection in people who are at high risk of infection. According to the documents, PrEP has shown efficacy in preventing HIV acquisition in uninfected individuals, with a high degree of efficacy (>90\\%) if subjects adhere strictly to the regimen. This indicates that PrEP is available and effective for preventing HIV infection in certain individuals. However, the question asks if there is no drug available to prevent HIV infection. The correct answer should be based on the understanding that PrEP is indeed a drug that prevents HIV infection, but the question might be trying to distinguish it from post-exposure prophylaxis (PEP), which is a treatment given after exposure to HIV to prevent infection. The documents also mention that two reverse transcriptase inhibitors have shown efficacy in trials for PrEP, and combined daily use of both drugs taken orally has demonstrated an over 90% reduction in the risk of HIV infection. Therefore, PrEP is indeed a drug that prevents HIV infection, making the correct answer incorrect. The correct interpretation of the question might be that there is no drug available to PREVENT HIV infection, but there is a drug available to PREVENT HIV infection in high-risk individuals (PrEP). However, this is a subtle distinction and the question might be trying to trick the test-taker. Given the information provided, the correct answer to the question as written would be based on the assumption that the question is asking if there is a drug available to PREVENT HIV infection in general, not specifically PrEP. The documents do not mention a drug that can prevent HIV infection in general, but they do mention PrEP, which is a form of prevention. Therefore, the correct answer to the question as written is not explicitly stated in the documents, but based on the information provided, the correct answer would be that there is a drug available to PREVENT HIV infection (PrEP), but the question might be trying to trick the test-taker into selecting an answer that indicates there is no drug available to prevent HIV infection in general. The best answer to the question as written would be B. no, because there is a drug available to PREVENT HIV infection (PrEP), but the question is phrased in a way that might lead to confusion. However, based on the information provided and the way the question is phrased, the best answer is B. no, because the documents do not mention a drug that can prevent HIV infection in general, but they do mention PrEP, which is a form of prevention.\", \"answer_choice\": \"B\"}",
    "snippets": [
        {
            "id": "Immunology_Janeway_3389",
            "title": "Immunology_Janeway",
            "content": "improvements in which have led to products that show promise in recent trials. Some of these agents can also reduce the transmission of other sexually transmitted diseases (for example, genital herpes) that increase the risk of HIV transmission. Finally, there is increasing interest in the prophylactic use of antiretroviral drugs (referred to as preexposure prophylaxis, or PrEP), which are administered either topically or orally to individuals at high risk for contracting HIV. To date, two reverse transcriptase inhibitors have shown efficacy in trials, and combined daily use of both drugs taken orally has demonstrated over 90% reduction in the risk of HIV infection. Moreover, use of antiretroviral therapy immediately postexposure\u2014for example, in hospital workers exposed to contaminated blood by accidental needlestick\u2014substantially reduces the risk of acquiring HIV. One concern with this approach is the risk of developing drug resistance in those who do contract HIV while on PrEP,"
        },
        {
            "id": "InternalMed_Harrison_14874",
            "title": "InternalMed_Harrison",
            "content": "Rare HIV transmission after nonintact skin exposure has been documented, but the average risk for transmission by this route has not been precisely determined; however, it is estimated to be less than the risk for mucous membrane exposure. Transmission of HIV through intact skin has not been documented. Currently in developed countries, virtually all puncture wounds and mucous membrane exposures in health care workers involving blood from a patient with documented HIV infection are treated prophylactically with combination antiretroviral therapy (cART). This practice, referred to as postexposure prophylaxis or PEP, has dramatically reduced the occurrence of puncture-related transmissions of HIV to health care workers."
        },
        {
            "id": "InternalMed_Harrison_15430",
            "title": "InternalMed_Harrison",
            "content": "include known or suspected pregnancy or breast-feeding, the possibility of exposure to drug-resistant virus, and toxicities of PEP regimens. Regardless of the decision to use PEP, the wound should be cleansed immediately and antiseptic applied. If a decision is made to offer PEP, U.S. Public Health Service guidelines recommend (1) a combination of two nucleoside analogue reverse transcriptase inhibitors given for 4 weeks for less severe exposures, or (2) a combination of two nucleoside analogue reverse transcriptase inhibitors plus a third drug given for 4 weeks for more severe exposures. Most clinicians administer the latter regimen in all cases in which a decision is made to treat. Detailed guidelines are available from the Updated U.S. Public Health Service Guidelines for the Management of Occupational Exposures to HIV and Recommendations for Postexposure Prophylaxis (CDC, 2005). The report emphasizes the importance of adherence to PEP when it is indicated, follow-up of exposed"
        },
        {
            "id": "InternalMed_Harrison_15447",
            "title": "InternalMed_Harrison",
            "content": "sexual act performed (see \u201cTransmission,\u201d above). Topical microbicides composed of gels containing antiretroviral drugs have been shown to be efficacious in preventing acquisition of HIV infection in women engaging in vaginal intercourse. However, there has been a considerable degree of variability in efficacy related to the variable adherence of participants to the use of the intervention. In general, it is felt that microbicides can be quite efficacious; however, adherence is a major stumbling block to 1285 their broad effectiveness. Pre-exposure prophylaxis (PreP) using oral antiretroviral drugs on a daily basis in uninfected men who have sex with men and transgender women has been shown to be efficacious in preventing acquisition of HIV infection. The degree of efficacy can be very high (>90%) if subjects adhere strictly to the regimen. However, adherence has proven to be a problem in maximizing the overall effectiveness of this approach."
        },
        {
            "id": "InternalMed_Harrison_15432",
            "title": "InternalMed_Harrison",
            "content": "For consultation on the treatment of occupational exposures to HIV and other bloodborne pathogens, the clinician managing the exposed patient can call the National Clinicians\u2019 Post-Exposure Prophylaxis Hotline (PEPline) at 888-448-4911. This service is available 24 hours a day at no charge. (Additional information on the Internet is available at www.nccc.ucsf.edu.) PEPline support may be especially useful in challenging situations, such as when drug-resistant HIV strains are suspected or the health care worker is pregnant. Health care workers can minimize their risk of occupational HIV infection by following the CDC guidelines of July 1991, which include adherence to universal precautions, refraining from direct patient care if one has exudative lesions or weeping dermatitis, and disinfecting and sterilizing reusable devices employed in invasive procedures."
        },
        {
            "id": "Surgery_Schwartz_1249",
            "title": "Surgery_Schwartz",
            "content": "HIV has significantly decreased the risk of seroconversion for healthcare workers with occupational exposure to HIV. Steps to initiate postexposure prophylaxis should be initiated within hours for the most effec-tive preventive therapy. Postexposure prophylaxis with a three-drug regimen should be initiated for healthcare workers with significant exposure to patients with an HIV-positive status. If a patient\u2019s HIV status is unknown, it may be advisable to begin postexposure prophylaxis while testing is carried out, particu-larly if the patient is at high risk for infection due to HIV (e.g., has had a history of intravenous drug use). Generally, postexpo-sure prophylaxis is not warranted for exposure to sources with unknown status, such as deceased persons or needles from a sharps container.92The risks of acquiring HIV infection for surgeons are related to the prevalence of HIV infection in the patient popula-tion, the probability of transmission from a percutaneous injury suffered"
        },
        {
            "id": "Immunology_Janeway_3390",
            "title": "Immunology_Janeway",
            "content": "blood by accidental needlestick\u2014substantially reduces the risk of acquiring HIV. One concern with this approach is the risk of developing drug resistance in those who do contract HIV while on PrEP, particularly in individuals with poor adherence to the dosing regimen. Although the significance of this risk has yet to be established, it remains an issue. Nevertheless, testing of new PrEP strategies based on additional antiretrovirals or of longacting formulations that reduce the risk of poor compliance represents areas of considerable promise."
        },
        {
            "id": "Obstentrics_Williams_9079",
            "title": "Obstentrics_Williams",
            "content": "healthy woman with HIV has no signiicant efect on disease Vertical transmission is increased by breastfeeding, and it genprogression (Calvert, 2015). Linkage to general HIV care posterally is not recommended for HIV-positive women in the partum is critical to maintain viral suppression (Swain, 2016). United States, where formula is readily available (Read, 2003). For women who do not have HIV infection, but whose In nutritionally deprived countries, where infectious disease partner is seropositive, current guidance supports the use of and malnutrition are primary causes of infant death, the World highly active antiretroviral therapy with viral suppression in the Health Organization (2016) recommends exclusive breastfeeding infected partner (treatment as prevention), and consideration during the first 6 to 12 months. of antiretroviral preexposure prophylaxis (PreP) for the HIV he Panel on Treatment of HI V-Infected Pregnant Women negative partner. The well-counseled couple can consider"
        },
        {
            "id": "InternalMed_Harrison_11321",
            "title": "InternalMed_Harrison",
            "content": "The employee health service must have protocols for dealing with workers exposed to contagious diseases (e.g., influenza) and those percutaneously or mucosally exposed to the blood of patients infected with HIV or hepatitis B or C virus. For example, postexposure HIV prophylaxis (PEP) with combination antiretroviral agents is recommended, as indicated; free consultation is available from the CDC-funded PEPLine (888-HIV-4911). Protocols are also needed for dealing with caregivers who have common contagious diseases (such as chickenpox, group A streptococcal infection, influenza or another respiratory infection, or infectious diarrhea) and for those who have less common but high-visibility public health problems (such as chronic hepatitis B or C or HIV infection) for which exposure-control guidelines have been published by the CDC and by the Society for Healthcare Epidemiology of America."
        },
        {
            "id": "InternalMed_Harrison_15449",
            "title": "InternalMed_Harrison",
            "content": "cultural and social factors that contribute to the sharing of paraphernalia are complex and difficult to overcome. In addition, needles and syringes may be in short supply. Under these circumstances, paraphernalia should be cleaned after each usage with a virucidal solution, such as undiluted sodium hypochlorite (household bleach). Programs that provide sterile needles to addicts in exchange for used needles have resulted in a marked decrease in HIV transmission without increasing the use of injection drugs. It is important for IDUs to be tested for HIV infection and counseled to avoid transmission to their sexual partners. Oral PreP also is effective in preventing acquisition of HIV infections among IDUs. Prevention of transmission through blood or blood products and prevention of mother-to-child transmission are discussed in \u201cTransmission,\u201d above."
        },
        {
            "id": "Obstentrics_Williams_9080",
            "title": "Obstentrics_Williams",
            "content": "the first 6 to 12 months. of antiretroviral preexposure prophylaxis (PreP) for the HIV he Panel on Treatment of HI V-Infected Pregnant Women negative partner. The well-counseled couple can consider periand Prevention of Perinatal Transmission (2016) strongly recovulatory condomless intercourse, or uterine insemination or ommends that ART regimens not be discontinued postpartum in vitro fertilization after sperm washing for assisted conception but continued lifelong for the advantages of viral suppression. (Brooks, 2017; Kawwass, 2017). Ideally, all those planning pregnancy should be receiving ART If, instead, pregnancy is undesired, efective contraception is and have a plasma viral load below detectable levels before discussed (Chap. 38, p. 680). Counseling also includes education conception. As one benefit, interpregnancy viral load suppresfor decreasing high-risk sexual behaviors to prevent transmission sion is associated with less vertical transmission in a subsequent and to"
        },
        {
            "id": "Pharmacology_Katzung_7345",
            "title": "Pharmacology_Katzung",
            "content": "Postexposure: 0.02 mL/kg IM as soon as possible after exposure up to 2 weeks. Hepatitis B Hepatitis B immune 0.06 mL/kg IM as soon as possible after globulin (HBIG) exposure up to 1 week for percutaneous exposure or 2 weeks for sexual exposure. 0.5 mL IM within 12 hours after birth for perinatal exposure. HIV-infected Immune globulin (IV)2 400 mg/kg IV every 28 days. children Preexposure and postexposure hepatitis A prophylaxis. The availability of hepatitis A vaccine has greatly reduced the need for preexposure prophylaxis. Patients >40 years should receive hepatitis A vaccine in addition to immune globulin for postexposure prophylaxis Postexposure prophylaxis in nonimmune persons following percutaneous, mucosal, sexual, or perinatal exposure. Hepatitis B vaccine should also be administered. HIV-infected children with recurrent serious bacterial infections or hypogammaglobulinemia."
        },
        {
            "id": "Surgery_Schwartz_1248",
            "title": "Surgery_Schwartz",
            "content": "workers with likely occupationally acquired HIV infection (n = 200), surgeons were one of the lower risk groups (compared to nurses at 60 cases and nonsur-geon physicians at 19 cases).91 The estimated risk of transmis-sion from a needlestick from a source with HIV-infected blood is estimated at 0.3%. Transmission of HIV (and other infections spread by blood and body fluid) from patient to healthcare worker can be minimized by observation of universal precau-tions, including: (a) routine use of barriers (gloves, gown, mask, eye protection) when anticipating contact with blood or body fluids, (b) washing hands and other skin surfaces immediately after contact with blood or body fluids, and (c) careful handling and disposal of sharp instruments during and after use.Postexposure prophylaxis for HIV has significantly decreased the risk of seroconversion for healthcare workers with occupational exposure to HIV. Steps to initiate postexposure prophylaxis should be initiated within hours for"
        },
        {
            "id": "Gynecology_Novak_1487",
            "title": "Gynecology_Novak",
            "content": "between the sexual assault and the initiation of therapy, and the patient\u2019s desire to be treated. All survivors of unprotected vaginal or anal sexual assault presenting within 72 hours should be offered HIV prophylaxis unless the assailant is known and tests negative with rapid HIV testing (169). Treatment should be initiated as soon as possible. The usual regimen is Combivir or its equivalent (300 mg zidovudine [AZT] and 150 mg lamivudine [3TC]) administered twice daily for 4 weeks). Administration of a protease inhibitor (nelfinavir, five 250 mg tablets twice a day for 28 days) should be considered for high-risk exposures, such as when the assailant is known to be HIV infected. Providers should also consider consulting an HIV specialist or calling the National Clinicians\u2019 Post-Exposure Prophylaxis Hotline. Side effects of HIV prophylaxis include nausea, malaise, headache, and anorexia. About 33% of survivors who elect to take antiviral medication discontinue therapy prematurely"
        },
        {
            "id": "Immunology_Janeway_3386",
            "title": "Immunology_Janeway",
            "content": "The spread of HIV can be prevented if precautions are taken by those already infected and those who are uninfected but at risk for exposure. The advent of HAART represents a major advance in blocking the transmission of HIV from infected people due to its ability to greatly reduce viral titers in body fluids. However, most who are infected with HIV do not have access to HAART, as it is expensive and requires lifelong treatment, and many of those infected are unaware that they carry the virus. Even where HAART is unavailable, access to regular screening for those at risk is critical to inform those infected so they can take measures to avoid passing the virus to others. This, in turn, requires strict confidentiality and mutual trust. A barrier to the control of HIV is reluctance of individuals to find out whether they are infected, especially as one of the consequences of a positive HIV test is stigmatization by society. Here, education becomes an important component of the prevention"
        },
        {
            "id": "InternalMed_Harrison_14872",
            "title": "InternalMed_Harrison",
            "content": "Exposures that place a health care worker at potential risk of HIV infection are percutaneous injuries (e.g., a needle stick or cut with a sharp object) or contact of mucous membrane or nonintact skin (e.g., exposed skin that is chapped, abraded, or afflicted with dermatitis) with blood, tissue, or other potentially infectious body fluids. Large, multi-institutional studies have indicated that the risk of HIV transmission following skin puncture from a needle or a sharp object that was contaminated with blood from a person with documented HIV infection is ~0.3% and after a mucous membrane exposure it is 0.09% (see \u201cHIV and the Health Care Worker,\u201d below) if the injured and/or exposed person is not treated within 24 h with antiretroviral drugs. The risk of hepatitis B virus (HBV) infection following a similar type of exposure is ~6\u201330% in nonimmune individuals; if a susceptible worker is exposed to HBV, postexposure prophylaxis with hepatitis B immune globulin and initiation of HBV"
        },
        {
            "id": "InternalMed_Harrison_12252",
            "title": "InternalMed_Harrison",
            "content": "However, the frequent use of prepara-public health education, individual patient counseling, and behavior tions that contain nonoxynol 9 is associated with mucosal disruption modification. Sexually active persons, especially adolescents, should that paradoxically may enhance the risk of HIV infection in the event be offered screening for STIs. For male patients, a NAAT on urine of exposure. All patients should be instructed to refer sex partners for or a urethral swab may be used for screening. Preventing the spread evaluation and treatment. All sex partners of persons with gonorrhea of gonorrhea may help reduce the transmission of HIV. No effective should be evaluated and treated for N. gonorrhoeae and C. trachoma-vaccine for gonorrhea is yet available, but efforts to test several can-tis infections if their last contact with the patient took place within didates are under way. 60 days before the onset of symptoms or the diagnosis of infection in the patient. If the patient\u2019s last"
        },
        {
            "id": "InternalMed_Harrison_15364",
            "title": "InternalMed_Harrison",
            "content": "strict adherence to prescribed regimens of antiretroviral drugs. This 1273 has been facilitated by the coformulations of antiretrovirals and the development of once-daily regimens. Unfortunately, many of the most important questions related to the treatment of HIV disease currently lack definitive answers. Among them are the questions of when therapy should be started, what the best initial regimen is, when a given regimen should be changed, and what it should be changed to when a change is made. Notwithstanding these uncertainties, the physician and patient must come to a mutually agreeable plan based on the best available data. In an effort to facilitate this process, the U.S. Department of Health and Human Services makes available on the Internet (www.aidsinfo.nih.gov) a series of periodically updated guidelines, including \u201cGuidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents\u201d and \u201cGuidelines for the Prevention of Opportunistic Infections in"
        },
        {
            "id": "Pharmacology_Katzung_5403",
            "title": "Pharmacology_Katzung",
            "content": "Tenofovir disoproxil fumarate is one of the NRTI agents recommended for use in pregnancy (Table 49\u20135). The combination of tenofovir and emtricitabine is recommended as pre-exposure prophylaxis to reduce HIV acquisition in high-risk persons."
        },
        {
            "id": "Immunology_Janeway_3385",
            "title": "Immunology_Janeway",
            "content": "In addition to the biological obstacles to developing effective HIV vaccines, there are difficult ethical issues. It would be unethical to conduct a vaccine trial without trying at the same time to minimize the exposure of a vaccinated population to the virus itself. The effectiveness of a vaccine can, however, only be assessed in a population in which the exposure rate to the virus is high enough to assess whether vaccination protects against infection. This means that initial vaccine trials might have to be conducted in countries where the incidence of infection is very high and public health measures have not yet succeeded in reducing the spread of HIV. 13-38 Prevention and education are important in controlling the spread of HIV and AIDS."
        },
        {
            "id": "Obstentrics_Williams_9061",
            "title": "Obstentrics_Williams",
            "content": "he initial laboratory screening test for HIV is an antigen/ antibody combination immunoassay that detects antibodies against HIV-1 and HIV-2 and detects HIV-1 p24 antigen (Centers for Disease Control and Prevention, 2014). Antibody can be detected in most patients within 1 month of infection, and thus, antibody serotesting may not exclude early infection. Instead, for acute primary HIV infection, identiication of viral p24 core antigen or viral RNA is possible. No further testing is required for specimens that are negative on the initial immunoassay unless a known exposure to HIV has occurred."
        },
        {
            "id": "InternalMed_Harrison_23583",
            "title": "InternalMed_Harrison",
            "content": "For pre-exposure prophylaxis against hepatitis B in settings of frequent exposure (health workers exposed to blood; first-responder public safety workers; hemodialysis patients and staff; residents and staff of custodial institutions for the developmentally handicapped; injection drug users; inmates of long-term correctional facilities; persons with multiple sexual partners or who have had a sexually transmitted disease; men who have sex with men; persons such as hemophiliacs who require long-term, high-volume therapy with blood derivatives; household and sexual contacts of persons with chronic HBV infection; persons living in or traveling extensively in endemic areas; unvaccinated children under the age of 18; unvaccinated children who are Alaskan natives, Pacific Islanders, or residents in households of first-generation immigrants from endemic countries; persons born in countries with a prevalence of HBV infection \u22652%; patients with chronic liver disease; persons <age 60 with"
        },
        {
            "id": "InternalMed_Harrison_15410",
            "title": "InternalMed_Harrison",
            "content": "At present, the U.S. Department of Health and Human Services Guidelines panel recommends that everyone with HIV infection be treated with cART. The evidence for this is strongest for patients with CD4+ T cell counts <350/\u03bcL. Clinical trials are underway to more carefully determine the benefit of initiating therapy in patients with CD4+ T cell counts \u2265350/\u03bcL. In addition, one may wish to administer a 6-week course of therapy to uninfected individuals immediately following a high-risk exposure to HIV. The combination of tenofovir and emtricitabine is also indicated for pre-exposure prophylaxis in individuals at high risk of HIV infection. For patients diagnosed with an opportunistic infection and HIV infection at the same time, one may consider a 2to 4-week delay in the initiation of antiretroviral therapy during which time treatment is focused on the opportunistic infection. This delay may decrease the severity of any subsequent immune reconstitution inflammatory syndrome by lowering"
        },
        {
            "id": "InternalMed_Harrison_10764",
            "title": "InternalMed_Harrison",
            "content": "Screening Questions: Do you have any reason to think you might have a sexually transmitted infection? If so, what reason? For all adolescents <18 years old: Have you begun having any kind of sex yet? STD History: (3) Have you ever had any sexually transmitted infections or any genital infections? If so, which ones? Sexual Preference: (4) Have you had sex with men, women, or both? Injection Drug Use: Have you ever injected yourself (\u201cshot up\u201d) with drugs? (If yes, have you ever shared needles or injection equipment?) Have you ever had sex with a gay or bisexual man or with anyone who had ever injected drugs? Characteristics of Partner(s): Has your sex partner had any sexually transmitted infections? If so, which ones? Has your sex partner had other sex partners during the time you\u2019ve been together? STD Symptoms Checklist: (9) Have you recently developed any of these symptoms?"
        },
        {
            "id": "Surgery_Schwartz_1282",
            "title": "Surgery_Schwartz",
            "content": "Hosp Epidemiol. 2012;33(12):1242-1245. 90. Calfee DP. Methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci, and other Gram-positives in healthcare. Curr Opin Infect Dis. 2012;25(4):385-394. 91. Centers for Disease Control and Prevention. Surveillance of occupationally acquired HIV/AIDS in healthcare personnel, as of December 2010. Available at https://www.cdc.gov/HAI/organisms/hiv/Surveillance-Occupationally-Acquired-HIV-AIDS.html. Accessed July 31, 2017. 92. Updated U.S. Public Health Service guidelines for the manage-ment of occupational exposures to HIV and recommendations for postexposure prophylaxis. Downloaded from Centers for Disease Control and Prevention, Human Immunodeficiency Virus in Healthcare Settings, https://www.cdc.gov/hai/organ-isms/hiv/hiv.html. Accessed July 31, 2017. 93. Goldberg D, Johnston J, Cameron S, et al. Risk of HIV trans-mission from patients to surgeons in the era of post-exposure prophylaxis. J Hosp Infect."
        },
        {
            "id": "InternalMed_Harrison_9502",
            "title": "InternalMed_Harrison",
            "content": "Etiologic Category (% of Cases) Specific Causes Clostridium tetani, varicella-zoster virus, Clostridium botulinum toxin). Although the data suggesting efficacy are limited, IVIG is often used for patients with suspected staphylococcal or streptococcal toxic shock syndrome. When evaluating a patient with a suspected infectious disease, the physician must consider what infection control methods are necessary to prevent transmission of any possible infection to other people. In 2007, the U.S. Centers for Disease Control and Prevention published guidelines for isolation precautions that are available for download at www.cdc.gov/hicpac/2007IP/2007isolationPrecautions .html. Persons exposed to certain pathogens (e.g., N. meningitidis, HIV, Bacillus anthracis) should receive postexposure prophylaxis to prevent disease acquisition. (See relevant chapters for details on specific pathogens.)"
        },
        {
            "id": "InternalMed_Harrison_15431",
            "title": "InternalMed_Harrison",
            "content": "of Occupational Exposures to HIV and Recommendations for Postexposure Prophylaxis (CDC, 2005). The report emphasizes the importance of adherence to PEP when it is indicated, follow-up of exposed workers to improve PEP adherences, monitoring for adverse events (including seroconversion), and expert consultation in the management of exposures."
        },
        {
            "id": "InternalMed_Harrison_261",
            "title": "InternalMed_Harrison",
            "content": "Compared with the decision support methods discussed above, decision analysis represents a prescriptive approach to decision making in the face of uncertainty. Its principal application is risk, abundant uncertainty, trade-offs in the outcomes emphasizing a role for preferences, or absence of evidence due to an idiosyncratic feature. For a public health example, Fig. 3-3 displays a decision tree to evaluate strategies for screening for HIV infection. Infected individuals who are unaware of their illness cause up to of the initial diagnosis because of delayed diagnosis. Early identification offers the opportunity to prevent progression to AIDS through CD4 count and viral load monitoring and combination antiretroviral therapy and to reduce spread by reducing risky injection or sexual behaviors."
        },
        {
            "id": "InternalMed_Harrison_14521",
            "title": "InternalMed_Harrison",
            "content": "Prevention of CMV in organ and hematopoietic stem cell transplant recipients is usually based on one of two methods: universal prophylaxis or preemptive therapy. With universal prophylaxis, antiviral drugs are used for a defined period, often 3 or 6 months. One clinical trial demonstrated that, in CMV-seronegative recipients with seropositive donors, prophylaxis was more effective at prevention when given for 200 days rather than 100 days. With preemptive therapy, patients are monitored weekly for CMV viremia, and antiviral treatment is initiated once viremia is detected. Because of the bone marrow\u2013suppressive effects of universal prophylaxis, preemptive therapy is more commonly employed in hematopoietic stem cell transplant recipients. For patients with advanced HIV infection (CD4+ T cell counts of <50/\u03bcL), some experts have advocated prophylaxis with valganciclovir (see below). However, side effects, lack of proven benefit, possible induction of viral resistance, and high cost have"
        },
        {
            "id": "InternalMed_Harrison_11302",
            "title": "InternalMed_Harrison",
            "content": "Infection control practitioners institute a varicella exposure investigation and control plan whenever health care workers have been exposed to chickenpox (Chap. 217) or have worked while having or during the 24 h before developing chickenpox. The names of exposed workers and patients are obtained; medical histories are reviewed, and (if necessary) serologic tests for immunity are conducted; physicians are notified of susceptible exposed patients; postexposure prophylaxis with a preparation of varicella-zoster immune globulin (VZIG) is considered for immunocompromised or pregnant contacts, with administration as soon as possible (but as long as 10 days after expo-917 sure) (Table 217-1); varicella vaccine is recommended or preemptive use of acyclovir is considered as an alternative strategy in other susceptible persons; and susceptible exposed employees are furloughed during the at-risk period for disease (8\u201321 days or, if VZIG has been administered, 28 days). Routine varicella"
        },
        {
            "id": "InternalMed_Harrison_15078",
            "title": "InternalMed_Harrison",
            "content": "The CDC has recommended that screening for HIV infection be performed as a matter of routine health care. The diagnosis of HIV infection depends on the demonstration of antibodies to HIV and/or the direct detection of HIV or one of its components. As noted above, antibodies to HIV generally appear in the circulation 3\u201312 weeks following infection."
        },
        {
            "id": "Pediatrics_Nelson_2651",
            "title": "Pediatrics_Nelson",
            "content": "The approach to the numerous opportunistic infections in HIV-infected patients involves treatment and prophylaxis for infections likely to occur as CD4 cells are depleted. With potent antiretroviral therapy and immune reconstitution, routine prophylaxis for common opportunistic infections depends on the child\u2019s age and CD4 count. Infants born to HIV-infected mothers receive prophylaxis for P. jiroveci pneumonia with trimethoprim-sulfamethoxazole (TMP-SMZ) beginning at 4 to 6 weeks of age and continued for the first year of life or discontinued if HIV infection is subsequently excluded. TMP-SMZ prophylaxis for P. jiroveci pneumonia for older children and adolescents is provided if CD4 cell counts are less than 200/ mm3 or there is history of oropharyngeal candidiasis. Clarithromycin prophylaxis for Mycobacterium avium-complexinfection is provided if CD4 cell counts are below 50/mm3."
        }
    ],
    "scores": [
        0.03509529686000275,
        0.03394548766613474,
        0.033316525797297554,
        0.029413649531715023,
        0.026288244766505632,
        0.025052505250525055,
        0.025013842746400883,
        0.02486025301559282,
        0.02483644595359366,
        0.02445573508204441,
        0.02358058608058608,
        0.02325997471656501,
        0.023192184478235928,
        0.022725890832098524,
        0.02248168498168498,
        0.022385317536757147,
        0.02221867254369963,
        0.02119127834551047,
        0.020525767170582104,
        0.018725709288767975,
        0.01798057200356051,
        0.017900990099009903,
        0.017355371900826446,
        0.01707175925925926,
        0.016616008105369808,
        0.01655719759168035,
        0.016533442645350824,
        0.0158033890157433,
        0.01579601990049751,
        0.01562881562881563,
        0.015423023578363382,
        0.01536231884057971
    ]
}